LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

被引：4
|
作者：
El-Khoueiry, Anthony B.
Llovet, Josep M.
Vogel, Arndt
Madoff, David C.
Finn, Richard S.
Ogasawara, Sadahisa
Ren, Zhenggang
Mody, Kalgi
Li, Jerry J.
Siegel, Abby B.
Dubrovsky, Leonid
Kudo, Masatoshi
机构：
[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[3] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Catalonia, Spain
[4] Inst Catalana dEstudis Avancats ICREA, Barcelona, Spain
[5] Hannover Med Sch, Hannover, Germany
[6] Smilow Canc Hosp, Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[7] Smilow Canc Hosp, Yale New Haven Hlth, New Haven, CT USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[9] Chiba Univ, Grad Sch Med, Chiba, Japan
[10] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[11] NJ Merck Co Inc, Woodcliff Lake, Kenilworth, NJ USA
[12] Kindai Univ, Sch Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS494
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS494
引用
收藏
页数：3
相关论文
共 50 条
  • [1] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
    Llovet, J. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Madoff, D. C.
    Finn, R. S.
    Ogasawara, S.
    Ren, Z.
    Mody, K.
    Li, J. Jing
    Siegel, A. B.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S703
  • [2] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
  • [3] LEAP-012 TRIAL IN PROGRESS: PEMBROLIZUMAB, LENVATINIB, AND TRANSARTERIAL CHEMOEMBOLIZATION COMBINATION THERAPY FOR INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA NOT AMENABLE TO CURATIVE TREATMENT
    Vogel, Arndt
    Llovet, Josep M.
    El-Khoueiry, Anthony B.
    Madoff, David C.
    Finn, Richard
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    HEPATOLOGY, 2020, 72 : 697A - 698A
  • [4] Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (04) : 405 - 412
  • [5] Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
    Josep M. Llovet
    Arndt Vogel
    David C. Madoff
    Richard S. Finn
    Sadahisa Ogasawara
    Zhenggang Ren
    Kalgi Mody
    Jerry J. Li
    Abby B. Siegel
    Leonid Dubrovsky
    Masatoshi Kudo
    CardioVascular and Interventional Radiology, 2022, 45 : 405 - 412
  • [6] Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2024,
  • [7] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Ogasawara, S.
    Llovet, J.
    El-Khoueiry, A.
    Vogel, A.
    Madoff, D.
    Finn, R.
    Ren, Z.
    Modi, K.
    Li, J.
    Siegel, A.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S124 - S125
  • [8] Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma
    Xiang, Yan-Jun
    Wang, Kang
    Yu, Hong-Ming
    Li, Xiao-Wei
    Cheng, Yu-Qiang
    Wang, Wei-Jun
    Feng, Jin-Kai
    Bo, Meng-Han
    Qin, Ying-Yi
    Zheng, Yi-Tao
    Shan, Yun-Feng
    Zhou, Li-Ping
    Zhai, Jian
    Cheng, Shu-Qun
    HEPATOLOGY RESEARCH, 2022, 52 (08) : 721 - 729
  • [9] Therapeutic approaches in intermediate-stage hepatocellular carcinoma (HCC): a novel insight of adjuvant transarterial chemoembolization (TACE)
    Fernandez-Palanca, Paula
    Mauriz, Jose L.
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (02)
  • [10] A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol
    Nicholas Fidelman
    CardioVascular and Interventional Radiology, 2022, 45 : 413 - 414
12345